INQ000479901 - Report from Rapid C-19 Oversight Group, titled tixagevimab and cilgavimab (Evusheld, AZD7442; AstraZeneca) in pre-exposure prophylaxis, dated 24/08/2022.

You are using a web browser with JavaScript disabled. Some of the features of this website may not function as intended.

Report from Rapid C-19 Oversight Group, titled tixagevimab and cilgavimab (Evusheld, AZD7442; AstraZeneca) in pre-exposure prophylaxis, dated 24/08/2022.

Module 4 adduced:

• Pages 1, 6-8, 10-12 and 16 on 30 January 2025

Download this document

English (PDF)